Alpha-Blocker Plus Diuretic Combination Therapy as Second-Line Treatment for Nocturia in Men - Full Text View

Sponsored by:	Seoul National University Hospital
Information provided by:	Seoul National University Hospital
ClinicalTrials.gov Identifier:	NCT00700583

Purpose

The aim of the present study was to determine whether the combined administration of a diuretic agent, hydrochlorothiazide, at night would improve the frequency of nocturia unresponsive to alpha-blocker monotherapy in men with LUTS.

Condition	Intervention
Nocturia	Drug: combination therapy of terazosin and hydrochlorothiazide

Study Type:	Interventional
Study Design:	Treatment, Uncontrolled, Single Group Assignment
Official Title:	Alpha-Blocker Plus Diuretic Combination Therapy as Second-Line Treatment for Nocturia in Men With LUTS: a Pilot Study

Resource links provided by NLM:

MedlinePlus related topics: Urine and Urination

Drug Information available for: Hydrochlorothiazide Terazosin

U.S. FDA Resources

Further study details as provided by Seoul National University Hospital:

Primary Outcome Measures:

3-day frequency-volume chart [ Time Frame: at baseline and at the end of the 4-week therapy ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

International Prostate Symptom Score (IPSS) question 7 [ Time Frame: at baseline and at the end of the 4-week therapy ] [ Designated as safety issue: No ]

Enrollment:	72
Study Start Date:	May 2008
Study Completion Date:	June 2008
Primary Completion Date:	June 2008 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Experimental	Drug: combination therapy of terazosin and hydrochlorothiazide 25 mg of hydrochlorothiazide eight hours before bedtime and 4 mg of terazosin at bedtime for 4 weeks

Detailed Description:

Because nocturia may result in sleep disturbances, daytime fatigue, a lower level of general well-being, and an increased risk of falling at night, it is among the most bothersome of the lower urinary tract symptoms (LUTS). Nocturia is related to a variety of conditions such as aging, overactive bladder (OAB), benign prostatic hyperplasia (BPH)/LUTS, medications, diabetes mellitus, diabetes insipidus, anorexia nervosa, and sleep disturbance. In a previous study, we suggested that treatment with terazosin can reduce episodes of nocturia, both subjectively and objectively, in some men with LUTS.

Other study showed that in men with nocturnal polyuria, furosemide resulted in a significant reduction in night-time frequency and percentage of the voided volume.

Eligibility

Genders Eligible for Study:	Male
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

no response or < 25% reduction in subjective nocturia by the IPSS question 7 after 4-weeks of treatment with terazosin
no response or < 25% reduction in objective nocturia by the FVC after 4-weeks of treatment with terazosin
nocturia on average two times or more per night (according to the FVC) after 4-weeks of terazosin therapy

Exclusion Criteria:

use of medications for the control of bladder symptoms
use of sedatives or tranquillisers for treating sleep disturbances
bladder tumours
bladder stones
urethral strictures
neurogenic bladder dysfunction
restricted mobility
working primarily at night
a documented history or clinical symptoms of prostatitis, prostate cancer, or prostatic intraepithelial neoplasia on biopsy
serum PSA levels of >20 ng/mL
a history of prostate surgery or radiotherapy, acute urinary retention or an indwelling catheter
evidence of acute urinary infection (pyuria and bacteriuria)on urine analysis

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00700583

Locations

Korea, Republic of
Department of Urology, Seoul National University Hospital
Seoul, Korea, Republic of, 110-744

Sponsors and Collaborators

Seoul National University Hospital

Investigators

Principal Investigator:

Min Chul Cho, M.D. Master

Department of Urology, Seoul National University College of Medicine

More Information

Publications:

Cho MC, Ku JH, Paick JS. Alpha-blocker plus diuretic combination therapy as second-line treatment for nocturia in men with LUTS: a pilot study. Urology. 2009 Mar;73(3):549-53; discussion 554-5. Epub 2008 Dec 18.

Study ID Numbers:	mccho
Study First Received:	June 16, 2008
Last Updated:	March 12, 2009
ClinicalTrials.gov Identifier:	NCT00700583 History of Changes
Health Authority:	Korea: Food and Drug Administration

Keywords provided by Seoul National University Hospital:

nocturia
bladder
urination disorders
hydrochlorothiazide
terazosin

Study placed in the following topic categories:

Nocturia
Neurotransmitter Agents
Adrenergic Agents
Urination Disorders
Diuretics
Sodium Chloride Symporter Inhibitors
Adrenergic alpha-Antagonists

Cardiovascular Agents
Antihypertensive Agents
Hydrochlorothiazide
Terazosine
Signs and Symptoms
Adrenergic Antagonists

Additional relevant MeSH terms:

Nocturia
Neurotransmitter Agents
Adrenergic Agents
Molecular Mechanisms of Pharmacological Action
Sodium Chloride Symporter Inhibitors
Physiological Effects of Drugs
Diuretics
Cardiovascular Agents
Adrenergic alpha-Antagonists
Antihypertensive Agents

Hydrochlorothiazide
Pharmacologic Actions
Terazosine
Membrane Transport Modulators
Urological Manifestations
Signs and Symptoms
Natriuretic Agents
Therapeutic Uses
Adrenergic Antagonists

ClinicalTrials.gov processed this record on July 02, 2009